SHARE: Change: 0.05 SEK / Bid: 9.95 SEK / Ask: 10.00 SEK / Price: 10.00 SEK / High: 10.00 SEK / Low: 9.60 SEK / Quantity: 5990 / Turnover: 59 577 SEK / 2017-09-18 22.00

Press releases

The board of Spago Nanomedical AB (publ) resolves on a rights issue prior to clinical studies

PRESS RELEASE Lund 22 August 2017 The Board of Directors (the “Board”) of Spago Nanomedical AB (publ) ("Spago" or the “Company") has given notice for an extraordinary general meeting to be held for the purpose of approving the Board's resolution regarding an issuance of units consisting of shares and warrants…
Read more

Spago Nanomedical and Charles River Laboratories announce agreement forpreclinical studies of SpagoPix

Spago Nanomedical has selected Charles River Laboratories, a leading global CRO, to conduct regulatory preclinical toxicology and safety studies of SpagoPix before clinical trials.
Read more

Annual General Meeting 2017

The annual general meeting will be held on May 17th, 15.30 at Advokatfirman Cederquist, Hovslagargatan 3 in Stockholm. For further information please follow the link below (in Swedish). Kallelse Spago AGM 2017
Read more

Anna Sundlöv nominated to the board of directors in Spago Nanomedical

Anna Sundlöv, clinical oncologist specialized in radionuclide therapy of cancer, is nominated to the board of Spago Nanomedical.
Read more

Promising results in toxicological pilot studies with SpagoPix

Collective data from recently completed toxicity studies show that the product candidate SN132D can be given safely at doses that widely exceeds the expected clinical dose.
Read more

Invitation to presentation of Spago Nanomedical AB’s year-end report for 2016

Spago Nanomedical AB publishes its year-end report for 2016 on February 14.
Read more

SpagoPix product patent approved in Japan

Spago Nanomedical announce today that the Japanese patent authorities has decided to approve the company´s patent application comprising the nanoparticles that are the foundation of the SpagoPix project.
Read more

Change of owner structure in Spago Nanomedical

Chairperson, CEO, and several major shareholders increase holding in Spago Nanomedical when 756,000 shares, ca. 9% of company total, are traded.
Read more

Spago Nanomedical appoints product candidate in the SpagoPix-project

The final formulation of the tumor-selective contrast agent SpagoPix has been biologically verified and fulfills the company criteria regarding tolerability and toxicity in pilot studies. SpagoPix is now ready for further development in regulatory studies.
Read more

Interim report January – June 2016 (in Swedish)

Perioden januari – juni i sammandrag   Periodens resultat uppgick till -4 436 Tkr (-4 170 Tkr). Resultat per aktie, före utspädning, uppgick till -0,56 kr (-0,75 kr). Likvida medel för koncernen uppgick vid utgången av perioden till 26 190 Tkr (7 071 Tkr).   Viktiga händelser under perioden Uppskalning…
Read more